CN

CN

News

Company News Industry News

Company News

MediLink Therapeutics Announces B7-H3 ADC YL201 Met Primary Endpoint in Phase 3 Nasopharyngeal Carcinoma Study

SUZHOU, China – May 29, 2026 – MediLink Therapeutics (Suzhou) Co., Ltd. today announced that tambotatug pelitecan (tam-peli, R&D code: YL201), its investigational B7-H3 targeted antibody-drug conjugate (ADC), has achieved positive results in the pre-specified interim analysis of the Phase 3 registrational clinical trial (TAISHAN-301) for recurrent or metastatic nasopharyngeal carcinoma (NPC). The Independent Data Monitoring Committee (IDMC) confirmed that the trial met the endpoint of confirmed objective response rate (cORR) as assessed by Blinded Independent Central Review (BICR), demonstrating a statistically significant improvement compared to chemotherapy. The second co-primary endpoint of overall survival (OS) is not yet mature. This marks the first positive Phase 3 result for any B7-H3 targeted ADC worldwide.

2026-05-30

Shining at ASCO 2026 | MediLink Therapeutics Presents Multiple Clinical Studies, Showcasing ADC Innovation

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will take place May 29 – June 2 in Chicago, IL. As the world’s largest, most influential, and authoritative oncology conference, ASCO drives global progress in cancer research, clinical development, and patient care.

2026-05-20

MediLink Therapeutics Presents Two Innovative ADC Programs at AACR 2026

MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), is pleased to share two cutting-edge research posters at the AACR 2026 Annual Meeting (April 17–22, San Diego, USA).

2026-04-23

MediLink’s YL217 received FDA Clearance of IND Application

February 1, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for YL217, an investigational antibody-drug conjugate (ADC) developed by MediLink. YL217 is the 11th ADC candidate entering into clinical stage developed based on MediLink’s proprietary TMALIN® technology platform.

2025-02-02Learn more

YL201 Received Another Breakthrough Therapy Designation for the Treatment of R/M NPC

January 20, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the Center for Drug Evaluation (CDE) granted Breakthrough Therapy Designation to YL201, for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). Previously, the Breakthrough Therapy Designation was also granted for YL201 by the CDE for the treatment of recurrent small cell lung cancer.

2025-01-20Learn more

MediLink Announces Collaboration with AstraZeneca to Explore the Combinational Potential of YL201 and Imfinzi®

Suzhou, China, Jan 14, 2025 -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, announced that a clinical collaboration has been established with AstraZeneca to explore the therapeutic potential in solid tumors, of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® ( durvalumab).

2025-01-14Learn more

MediLink Therapeutics Announces Strategic Partnership with Zai Lab to Develop a Novel LRRC15 Antibody-Drug Conjugate

SUZHOU, SHANGHAI and CAMBRIDGE, Mass., Jan 10, 2025 -- MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) today announced a new strategic collaboration and worldwide license agreement with Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.

2025-01-10Learn more

MediLink Announces YL201 Granted Orphan-Drug Designation by the US FDA

December 18, 2024 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation to YL201, for the treatment of small cell lung cancer (SCLC). YL201 is an investigational B7H3-targeted ADC, developed based on MediLink’s proprietary TMALIN® (Tumor Microenvironment Activable LINker) technology platform.

2024-12-18Learn more

MediLink successfully Held YL201 Investigator Meeting of a Phase III Study in Nasopharyngeal Carcinoma

December 1st, 2024 -- The investigator meeting of the phase III study in nasopharyngeal carcinoma for YL201, (a B7-H3 targeted antibody-drug conjugate), was held in Guangzhou, China. More than 70 experienced oncology experts from over 60 clinical sites (including many top oncologists from major academic cancer institutions across the country) attended the meeting to review and discuss the cutting-edge ADC technology in the treatment of nasopharyngeal carcinoma. The entire meeting was filled with an atmosphere of passion and a spirit of collaboration. YL201, a targeted antibody-drug conjugate is based on MediLink's TMALIN® platform and has received significant attention.

2024-12-02Learn more
1 2 3 4 5 6